NASDAQ · NAGE
Niagen Bioscience, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NAGE: Nov 04, 2026
Niagen Bioscience, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0. The reported EPS for the same quarter last year was $0.05.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.00 | $0.02 | $-0.03 | 2 |
| Dec 2026 | $-0.02 | $0.02 | $-0.06 | 2 |
| Mar 2027 | $0.01 | $0.03 | $0.00 | 2 |
| Jun 2027 | $0.01 | $0.03 | $0.00 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · RTTNews · Fintel- Zacks · Oct 28, 9:00 AM EDTEarnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to DeclineNiagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Aug 4, 5:40 PM EDTNiagen Bioscience (NAGE) Meets Q2 Earnings EstimatesNiagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 8:35 AM EDTBristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat EstimatesBristol Myers (BMY) delivered earnings and revenue surprises of +28.30% and +11.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 21, 7:05 AM EDTArmata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks · Jul 6, 11:15 AM EDTImplied Volatility Surging for Niagen Bioscience Stock OptionsInvestors need to pay close attention to NAGE stock based on the movements in the options market lately.
- Zacks · May 6, 6:30 PM EDTNiagen Bioscience (NAGE) Q1 Earnings and Revenues Top EstimatesNiagen Bioscience (NAGE) delivered earnings and revenue surprises of +16.67% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · May 6, 5:49 PM EDTNiagen (NAGE) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Mar 6, 2:05 AM ESTNiagen Bioscience FY25 Net Sales Jump 30%; Sees 10-15% Growth In FY26(RTTNews) – Niagen Bioscience Inc. (NAGE), a commercial-stage global bioscience company that is pioneering research on NAD+ for healthy aging, reported its fourth-quarter and full-year 2025 financial results and also released its 2026 sales outlook, projecting growth of 10-15%.
- The Motley Fool · Mar 4, 5:58 PM ESTNiagen Bioscience (NAGE) Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Mar 4, 5:35 PM ESTNiagen Bioscience (NAGE) Tops Q4 Earnings and Revenue EstimatesNiagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Nov 13, 7:03 AM ESTNiagen Biosciences Reports Results From First-ever Randomized Trial Of Niagen NR In Long COVID(RTTNews) – Niagen Biosciences, Inc. (NAGE), a global leader in NAD+ science and healthy ageing, announced results from its first randomised controlled trial evaluating Niagen – a patented nicotinamide riboside (NR) supplementation – in individuals with long COVID.
- Fintel · Nov 5, 7:08 PM ESTCanaccord Genuity Maintains Niagen Bioscience (NAGE) Buy RecommendationFintel reports that on November 5, 2025, Canaccord Genuity maintained coverage of Niagen Bioscience (NasdaqCM:NAGE) with a Buy recommendation. Analyst Price Forecast Suggests 137.80% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Niagen Bioscience, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.